10 January 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Publication of New Research

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to inform shareholders that a new research note on the Company has recently been published by Pitt Street Research.

The research can be found on the Company's website via the link below:

https://www.roquefortinvest.com/research-reports

ENDS

Enquiries:

For further information on Roquefort Therapeutics, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma.  The Company's wholly owned subsidiary, Lyramid Pty Ltd ("Lyramid"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19.  Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation. 

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Lyramid's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.